Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S2213-2600(23)00037-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Model for Consolidating High-Risk Allergy Procedures in Clinic.
Ochsner J
January 2024
Department of Allergy and Immunology, Ochsner Clinic Foundation, New Orleans, LA.
Allergists perform a range of procedures with inherent risks of anaphylaxis. This study developed risk assessments for various procedures performed at our specialized referral center based on the frequency of epinephrine use during these procedures. During a 5.
View Article and Find Full Text PDF[COVID-19 vaccine safety: results of active surveillance at a sentinel site in ArgentinaSegurança das vacinas contra COVID-19: resultados da vigilância ativa em uma unidade sentinela da Argentina].
Rev Panam Salud Publica
December 2024
Dirección de Control de Enfermedades Inmunoprevenibles Ministerio de Salud de la Nación Ciudad Autónoma de Buenos Aires Argentina Dirección de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Nación, Ciudad Autónoma de Buenos Aires, Argentina.
Objective: To analyze the results of surveillance of adverse events of special interest (AESI) within the context of the COVID-19 vaccination campaign at a sentinel site in Argentina. The retrospective (pre-vaccination) period was compared with the prospective (vaccination) period to identify safety signals.
Methods: Retrospective and prospective search for AESI based on ICD-10 hospital discharge codes.
Thinking like a Bayesian: Diagnostic food allergy testing at the extremes of clinical certainty.
Ann Allergy Asthma Immunol
December 2024
Schreiber Allergy, Rockville, Maryland.
Biologics in allergology and clinical immunology: Update on therapies for atopic diseases, urticaria, and angioedema and on safety aspects focusing on hypersensitivity reactions.
Allergol Select
November 2024
Institute of Allergology, Charité Universitätsmedizin Berlin und Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin.
Article Synopsis
- Targeted therapies using biologics for atopic diseases, urticaria, and angioedema are advancing quickly, with several new antibodies developed, tested, and approved for clinical use, like omalizumab and dupilumab.
- There is ongoing research into combining different biologics for enhanced treatment efficacy, expanding their applications to conditions like food allergies and eosinophilic esophagitis.
- There are emerging concerns about unexpected side effects and hypersensitivity reactions associated with these therapies, raising important questions about their safety and mechanisms, particularly in specific patient groups like children.
Safety and Immunogenicity of Intranasal Razi Cov Pars as a COVID-19 Booster Vaccine in Adults: Promising Results from a Groundbreaking Clinical Trial.
Vaccines (Basel)
November 2024
Department of Immunology, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), P.O. Box 31975/148, Karaj, Iran.
Protective antibodies in the upper respiratory tract prevent the spread of COVID-19 in the community. Intranasal vaccines could raise the specific secretory IgA and IgG levels. This is a single-center, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and immunogenicity of Razi Cov Pars (RCP) intranasal recombinant protein subunit COVID-19 vaccine as a booster in adults.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!